I am deeply driven by a passion for research and an unwavering curiosity to explore and learn. My journey in science has been shaped by a profound desire to uncover the unknown and push the boundaries of what is possible, particularly in the field of cancer immunotherapy. As a recent graduate with a Master's degree from Carnegie Mellon University (CMU), I have built a strong foundation in microbiology and bioengineering as well as Cancer immunotherapy. I have devoted myself to understanding the intricate interplay between tumor cells and the immune system, with the ultimate goal of developing innovative and effective treatments.

My work focuses on adoptive cell therapies, immune checkpoint blockade, and TIL (Tumor-Infiltrating Lymphocyte) therapy, with a particular emphasis on combining TIL therapy with neoantigen targeting for cancer treatment. I am excited by the potential of neoantigens to drive targeted therapies, and I aim to leverage this knowledge to improve cancer treatment outcomes. By utilizing advanced immunotherapies, I hope to enhance the precision and efficacy of cancer treatments, providing more effective and personalized care for patients.

The promise of groundbreaking discoveries fuels my passion, but I also thrive on continuous learning and growth. I embrace the iterative nature of research, tackling complex challenges, and exploring new ideas that drive the advancement of immuno-oncology. My commitment is to contribute meaningfully to its development and make a lasting impact on cancer treatment.